Conclusion of non-exclusive drug discount agreement for Sultiam
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultiam (ATC-Code nach WHO: N03AX03)
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescriptions and patient numbers. Revenue cannot be forecast.
The procedure may be terminated early if exclusive discount agreements are signed, causing all non-exclusive agreements...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2027
- Conclusion of non-exclusive drug discount agreements under §130a Abs.8 SGB V for Sultiam (N03AX03) in film tablets 50 mg and 200 mg
- Open-House model: any qualified pharmaceutical manufacturer can participate
Show full summary
Non-exclusive drug discount agreement for Sultiam (ATC N03AX03) in film tablets 50 mg and 200 mg via an Open-House model. Open to all qualified pharmaceutical companies. No guaranteed volumes, no exclusivity. Agreement ends 31 December 2027. Contracting authority: AOK PLUS for Saxony and Thuringia.
Risks
No minimum purchase quantities; actual demand depends on prescriptions and patient numbers. Revenue cannot be forecast.
The procedure may be terminated early if exclusive discount agreements are signed, causing all non-exclusive agreements...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical manufacturer as defined in §4 Abs.18 AMG
Eligibility
- Must submit declaration of no exclusion grounds (§§123,124 GWB)
Administrative
- Must submit Russia sanctions declaration
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Conclusion of non-exclusive drug discount agreement for Sultiam
Non-exclusive discount agreement for Sultiam (N03AX03) film tablets 50 mg and 200 mg. Open-House model, no exclusivity, no minimum purchase quantities.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Sultiam (ATC-Code nach WHO: N03AX03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 19 Feb 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 122067-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities; actual demand depends on prescriptions and patient numbers. Revenue cannot be forecast.
The procedure may be terminated early if exclusive discount agreements are signed, causing all non-exclusive agreements...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications